NCT02239835终止2 期
Tipranavir: An Open-label, Randomized Study Comparing Combination Therapy (Tipranavir and Ritonavir vs. Saquinavir and Ritonavir) Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 79
- 主要终点
- Number of patients with grade 3 and 4 laboratory abnormalities
研究概览
简要总结
Objectives of the study were to evaluate the efficacy and safety of two different doses of tipranavir (TPV) in combination with ritonavir (TPV/r) compared with a standard dual PI combination of saquinavir (SQV) and ritonavir (RTV) and to evaluate the dose response of two different doses of TPV in combination with RTV for efficacy and safety.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical failure while on the current PI-containing regimen of indinavir, nelfinavir, or amprenavir
- •In the investigator's opinion, adherence to the present PI-containing regimen
- •Exposure of >=6 months to the current PI therapy
- •Stable PI-containing regimen, i.e., receiving the current two reverse transcriptase inhibitors (RTIs) for at least 2 months prior to study entry
- •HIV-1 RNA >=1000 copies/mL (assayed using the Amplicor polymerase chain reaction (PCR) method at the initial screening visit)
- •No limit in CD4+ cell count at the initial screening
- •At least two new nucleoside reverse transcriptase inhibitor (NRTI) options available
- •Age >=18 years
- •Acceptable screening laboratory test values that indicated adequate baseline organ function at the time of screening. Acceptable laboratory test values consisted of the following: severity <=Grade 1 (ACTG Grading Scale). Stable Grade 2 abnormalities were permitted if the values had been demonstrated and documented for at least >=2 months. All laboratory values >Grade 2 were subject to approval by the P&U Clinical Program Leader or designated personnel and subsequently by the BI designated personnel
- •Acceptable medical history, physical examination, ECG, and chest radiograph prior to entry into the treatment phase of the study
- •Use of a barrier contraceptive method of birth control for at least 30 days prior to study drug administration, during the study, and 30 days after study completion
- •Ability to swallow numerous tablets and capsules without difficulty
- •Ability to understand and provide informed consent. Minors had to have approval of a parent or legal guardian
排除标准
- •Treatment with more than one PI-containing regimen
- •Clinically significant active or acute (onset within the month previous to study entry) medical problems, including the following: opportunistic infections, e.g., active cryptococcosis, Pneumocystis carinii pneumonia, herpes zoster, histoplasmosis, or cytomegalovirus; nonopportunistic diseases, including but not limited to the following: progressive multifocal leukoencephalopathy, lymphoma, or malignancy requiring systemic therapy
- •Prior exposure (>7 days) to tipranavir, saquinavir, or ritonavir
- •History of clinically significant nervous system or muscle diseases, seizure disorder, or psychiatric disorder that might impair adherence to the protocol
- •Taking of any known P450 3A enzyme-inducing drugs within 30 days of study entry and including the following: rifabutin, rifampin, carbamazepine, dexamethasone, phenobarbital, phenytoin, sulfadimidine, sulfinpyrazone, or troleandomycin
- •Hypersensitivity to tipranavir, saquinavir, or ritonavir
- •Use of interferons, interleukins, HIV vaccines, or any active immunizations within 30 days of study entry
- •Taking of any investigational medication with the exception of adefovir dipivoxil (Preveon™) within 30 days of study entry
- •Pregnancy or lactation (serum β-human chorionic gonadotrophin test had to have been negative within 14 days of study entry)
- •Evidence of substance abuse, which in the investigator's opinion could affect adherence to the protocol
- •In the investigator's judgment, inability to comply with the protocol requirements for reasons other than those specified
研究组 & 干预措施
SQV + RTV high dose
Active Comparator
干预措施: Ritonavir high dose (Drug)
SQV + RTV high dose
Active Comparator
干预措施: Saquinavir (Drug)
TPV low dose + RTV low dose
Experimental
干预措施: Tipranavir (TPV) low dose (Drug)
TPV low dose + RTV low dose
Experimental
干预措施: Ritonavir low dose (Drug)
TPV high dose + RTV low dose
Experimental
干预措施: Tipranavir (TPV) high dose (Drug)
TPV high dose + RTV low dose
Experimental
干预措施: Ritonavir low dose (Drug)
结局指标
主要结局
Number of patients with grade 3 and 4 laboratory abnormalities
时间窗: up to 96 weeks
Change from baseline in plasma HIV-1 RNA concentrations
时间窗: Week 16, 24 and 48
Occurrence of HIV-1 RNA levels below the limit of quantitation (BLQ)
时间窗: up to 96 weeks
using the Roche Amplicor HIV Monitor™ Method \[limit of detection (LD) 400 copies/mL\] and the Roche Amplicor UltraSensitive Method™ (LD 50 copies/mL)
Number of patients with treatment-emergent and drug-related adverse events (AEs)
时间窗: up to 96 weeks
Number of patients with serious adverse events (SAEs)
时间窗: up to 96 weeks
次要结局
- Change from baseline in cluster of differentiation (CD) 4+ cell count(Week 16, 24 and 48)
- Time to virologic failure(after week 16)
- Occurrence of new or recurring AIDS-defining illnesses(up to 96 weeks)
- Occurrence of HIV-1 related illness(up to 96 weeks)
- Occurrence of death(up to 96 weeks)
- Time to new or recurring AIDS-defining illnesses(up to 96 weeks)
- Time to HIV-1 related illness(up to 96 weeks)
- Time to death(up to 96 weeks)
- Change from baseline in blood glucose(up to 96 weeks)
- Change from baseline in cholesterol(up to 96 weeks)
- Change from baseline in high density lipoprotein (HDL)(up to 96 weeks)
- Change from baseline in triglycerides(up to 96 weeks)
- Time to virologic response(up to 96 weeks)
- Trough plasma tipranavir concentrations(up to week 24)
- Sequence-based HIV-1 analysis (genotyping) and drug susceptibility assays (phenotyping)(Baseline and week 24)
研究者
相似试验
已完成
3 期
Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)HIV InfectionsNCT00144170Boehringer Ingelheim882
已完成
2 期
Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV PatientsHIV InfectionsNCT02238314Boehringer Ingelheim41
终止
3 期
Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PIHIV InfectionsNCT00517192Boehringer Ingelheim40
已完成
1 期
Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in Human Immunodeficiency Virus (HIV)-Infected ChildrenHIV InfectionsNCT00076999Boehringer Ingelheim115
已完成
3 期
Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)HIV InfectionsNCT00054717Boehringer Ingelheim630